Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Norleucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.64 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.64 |
| ▸ | GSR | P00390 | 1/20 | 0.58 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.57 |
| ▸ | ARG2 | P78540 | 4/20 | 0.55 |
| ▸ | NOS1 | P29475 | 4/20 | 0.55 |
| ▸ | NOS2 | P35228 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norleucine SCHEMBL4163262 | 1.00 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL18586277 | 1.00 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL198127 | 0.98 | — | — | |
| Norleucine SCHEMBL5051846 | 0.98 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL8393 | 0.98 | — | — | |
| Norleucine SCHEMBL5497693 | 0.98 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL2785913 | 0.98 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL26474 | 0.98 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL8392 | 0.98 | — | — | |
| Norleucine SCHEMBL13736626 | 0.95 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116102443-A | Preparation method of 5-methyl aminopentanoate hydrochloride | 中国科学院上海药物研究所 | 2023-05-12 | — | — | CN | claimed |
| CN-111333641-B | Enhanced fluorescent probe for tetrazine bio-orthogonal labeling and synthesis thereof | 中国科学院大连化学物理研究所 | 2022-05-31 | — | — | CN | claimed |
| CN-111333645-B | Fluorescent probe for marking cytoskeleton | 中国科学院大连化学物理研究所 | 2021-10-15 | — | — | CN | claimed |
| CN-111925298-A | 4-CNAB and preparation method thereof | 无锡紫杉药业有限公司 | 2020-11-13 | — | — | CN | claimed |
| CN-111333641-A | Enhanced fluorescent probe for tetrazine bio-orthogonal labeling and synthesis thereof | 中国科学院大连化学物理研究所 | 2020-06-26 | — | — | CN | claimed |
| CN-111333645-A | Fluorescent probe for marking cytoskeleton | 中国科学院大连化学物理研究所 | 2020-06-26 | — | — | CN | claimed |
| CN-103910740-B | Tetrandrine derivant and preparation method thereof and the application in prepared by antitumor drug | 山东师范大学 | 2016-07-06 | — | — | CN | claimed |
| CN-102828283-A | Method for preparing chitosan and cellulose complex fibers by binary solvent system | UNIV DONGHUA | 2012-12-19 | — | — | CN | claimed |
| CN-102828284-A | Method for preparing high-strength chitosan fiber with binary solvent system | UNIV DONGHUA | 2012-12-19 | — | — | CN | claimed |
| CN-115362155-B | Arylamine derivative, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| CN-118103351-A | Coronavirus inhibitors | 共晶制药公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3724178-B1 | 1-(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| CN-114478283-B | Preparation method of 6-aminocaproic acid | 珠海联邦制药股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-5530016-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-06-25 | — | — | US | disclosed |
| EP-0419542-B1 | NEW DERIVATIVES OF TETRAHYDRO-2,3,6,7,1H,5H,11H-(1)BENZOPYRANO(6,7,8,IJ)QUINOLIZONONE-11 USABLE AS MARKERS FOR ORGANIC COMPOUNDS FOR THE PURPOSE OF DETECTING SAID COMPOUNDS BY CHEMILUMINESCENCE OR FLUORESCENCE | LABORATOIRES EUROBIO (FR) | 1993-09-29 | — | — | EP | disclosed |
| EP-0419542-A1 | NEW DERIVATIVES OF TETRAHYDRO-2,3,6,7,1H,5H,11H-(1)BENZOPYRANO(6,7,8,ij)QUINOLIZONONE-11 USABLE AS MARKERS FOR ORGANIC COMPOUNDS FOR THE PURPOSE OF DETECTING SAID COMPOUNDS BY CHEMILUMINESCENCE OR FLUORESCENCE. | EUROBIO LAB (FR) | 1991-04-03 | — | — | EP | disclosed |
| WO-1989012052-A1 | NEW DERIVATIVES OF TETRAHYDRO-2,3,6,7,1H,5H,11H-(1)BENZOPYRANO(6,7,8,ij)QUINOLIZONONE-11 USABLE AS MARKERS FOR ORGANIC COMPOUNDS FOR THE PURPOSE OF DETECTING SAID COMPOUNDS BY CHEMILUMINESCENCE OR FLUORESCENCE | LABORATOIRES EUROBIO (FR) | 1989-12-14 | — | — | WO | disclosed |
| US-4233099-A | Slide fastener method of manufacture | TEXTRON INC. (US) | 1980-11-11 | — | — | US | disclosed |
| US-4156303-A | Slide fastener with Nylon 6 and Nylon 6-6 binder seal and method of manufacture | TEXTRON INC. (US) | 1979-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | CA2 1597/4885SLC1A2 689/4885SLC1A1 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.